Short Term Trading Week Starting: 31 July

Originally posted by Lucretious: ↑

STTCOMP PCK TA LONG

Mkt cap $43m at 3.3c
SOI 1.3 billion (too many!)

Long term daily view

Been holder in PCK on and off but followed it since its inception. Chart shows a real roller coaster

These charts intrigue me, particularly when reviewing in light of the recent quarterly and the zoom preso made by Philip Daffas. I have gone with the TA rather than FA, but to be honest, its a blend. There was so much good stuff in the quarterly report with momentum gathering. A lot of good newsflow to come in the next 6 to 12 months, which is beyond the ST comp parameters I realise, but I think renewed interest may kick in here in the shorter term.

Price rose and fell all the way back to 2019 lows. Long term multiple bottom in place.

In short, the Company is kicking goals. more slowly than desired of course, but after 4 or 5 years of operation, much of it "subsidized" due to Government funding in a sector that attracted a lot of deserved criticism, is still with us and about to enter its next growth phase in my view.

It has survived the early years and is growing.

It has expanded to broader bigger markets of the UK and Canada and about to go into the US with partners for delivery established and now waiting FDA approval towards end of the year early next year.

More interestingly from a revenue perspective, the forthcoming infant app toward calendar year end could really bolster revenues.

Back to TA. Volumes near the bottom since May have held and volumes of trading have picked up. The low looks to be around 2.4. Current SP of 3.3 has market cap of c$43m.

It has broken a ST downtrend.
50 EMA has turned up and looks set to break through 200EMA which for the first time in years, is flat. ST EMA's at 9 and 21 have definietly turned up and breached the 50 EMA.

MACD rising and positive.

RSI rising

Immediate ST target is most recent highs at 4.2. Mkt cap would be c$55m
Next previous high around 6.7c = mkt cap of roughly $87m

In order to reach those next targets, new material contracts will need to be awarded. Those will most likely come from the UK Canada or the US when approved. Whilst they hold solid market share of aged care in Australia, the market is small, so overseas contracts have to be the go.

It is not out of the realms of possibility that the UK in particular, could sponsor Paincheck via the NHS. aged care is as big an issue in the UK as it is here and I have personal experience of this. The NHS is trying to use tech and AI to reduce costs and improve outcome. It is possible Palantir could win a half billion dollar contract with the NHS in the back half of this year on that front. They have already proven their worth with a couple of NHS Trusts in London. The point is that there is money to be spent on tech solutions if there is a clear economic case as well as solid patient outcomes

But the roll out of the infant app for parents could be huge.
FDA approval will open up a vast market and within a fairly short space of time PCK should get to cashflow positive.
And all he time they are accumulating vast amounts of data , which in itself is worth $'s

Expand

I wish you well with PCK - I had it as a legacy holding for dementia research but after years of holding I sold out a few weeks ago, over a number of days, as the volume was fairly large at a substantial loss,nice from a tax perspective, but frustrating from a complete lack of impetus from management (IMO) who promised plenty but failed to deliver.

Cheers V

I agree with @golden6